PE20021081A1 - ARIL AND BIARIL PIPERIDINES WITH MCH MODULATING ACTIVITY - Google Patents
ARIL AND BIARIL PIPERIDINES WITH MCH MODULATING ACTIVITYInfo
- Publication number
- PE20021081A1 PE20021081A1 PE2002000298A PE2002000298A PE20021081A1 PE 20021081 A1 PE20021081 A1 PE 20021081A1 PE 2002000298 A PE2002000298 A PE 2002000298A PE 2002000298 A PE2002000298 A PE 2002000298A PE 20021081 A1 PE20021081 A1 PE 20021081A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- biaril
- aril
- mch
- piperidines
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- -1 PYRIMIDINYL Chemical group 0.000 abstract 3
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 2
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Abstract
SE REFIERE A ARIL Y BIARIL PIPERIDINAS DE FORMULA I DONDE AR1 ES SELECCIONADO DEL GRUPO a, b, ENTRE OTROS; Z ES UN GRUPO R4-CO-, R4SO2-, R4N(R2')CO-, ENTRE OTROS; R2 ES H, ALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, CICLOALQUILO, ALQUILO, ARILALQUILO, ENTRE OTROS; R4 ES FENILO(SUSTITUIDO CON R7), FENILALQUILO, ENTRE OTROS; R5 ES R7, RENILO, PIRIDILO, TIOFENILO, PIRIMIDINILO SUSTITUIDO CON R7, ENTRE OTROS; R6 ES H, HALOGENO, ALQUILO, OH, ALCOXI, NH2, ENTRE OTROS; R7 ES H, HALOGENO, ALQUILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. SON COMPUESTOS PREFERIDOS ESTER TER-BUTILICO DE ACIDO 4-AMINOMETIL-4-(4-YODO-FENIL)-PIPERIDINA-1-CARBOXILICO, [4-(5-YODO-FENIL)-1-METIL-PIPERIDIN-4-IL]-METILAMINA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS TIENEN ACTIVIDAD MODULADORA RECEPTORA DE LA HORMONA CONCENTRADORA DE MELANINA (MCH) Y SON UTILES PARA EL TRATAMIENTO OBESIDAD, DIABETESREFERS TO ARIL AND BIARIL PIPERIDINES OF FORMULA I WHERE AR1 IS SELECTED FROM GROUP a, b, AMONG OTHERS; Z IS A GROUP R4-CO-, R4SO2-, R4N (R2 ') CO-, AMONG OTHERS; R2 IS H, ALKYL, AMONG OTHERS; R3 IS H, ALKYL, CYCLOALKYL, ALKYL, ARYLALKYL, AMONG OTHERS; R4 IS PHENYL (SUBSTITUTED WITH R7), PHENYLALKYL, AMONG OTHERS; R5 IS R7, RENYL, PYRIDYL, THIOPHENYL, PYRIMIDINYL SUBSTITUTED WITH R7, AMONG OTHERS; R6 IS H, HALOGEN, ALKYL, OH, ALCOXY, NH2, AMONG OTHERS; R7 IS H, HALOGEN, RENT, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. PREFERRED COMPOUNDS TER-BUTYL ESTER OF 4-AMINOMETIL-4- (4-IODO-PHENYL) -PIPERIDINE-1-CARBOXYL, [4- (5-IODO-PHENYL) -1-METHYL-PIPERIDIN-4-IL] -METILAMINE, AMONG OTHERS. THE MENTIONED COMPOUNDS HAVE RECEPTOR MODULATING ACTIVITY OF MELANIN CONCENTRATING HORMONE (MCH) AND ARE USEFUL FOR THE TREATMENT OF OBESITY, DIABETES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28352301P | 2001-04-12 | 2001-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20021081A1 true PE20021081A1 (en) | 2002-12-18 |
Family
ID=23086443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000298A PE20021081A1 (en) | 2001-04-12 | 2002-04-10 | ARIL AND BIARIL PIPERIDINES WITH MCH MODULATING ACTIVITY |
Country Status (11)
Country | Link |
---|---|
US (1) | US6887889B2 (en) |
EP (1) | EP1377293B1 (en) |
JP (2) | JP4280073B2 (en) |
AR (1) | AR035234A1 (en) |
AT (1) | ATE460163T1 (en) |
CA (1) | CA2443672C (en) |
DE (1) | DE60235617D1 (en) |
ES (1) | ES2340147T3 (en) |
MX (1) | MXPA03009353A (en) |
PE (1) | PE20021081A1 (en) |
WO (1) | WO2002083134A1 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1356816B1 (en) | 2001-01-29 | 2009-12-23 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
ES2319619T3 (en) | 2001-05-04 | 2009-05-11 | Amgen Inc. | CONDENSED HETEROCICLIC COMPOUNDS. |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
CN100548291C (en) | 2001-10-25 | 2009-10-14 | 先灵公司 | Be used for the treatment of fat MCH antagonist |
ATE446286T1 (en) * | 2001-11-26 | 2009-11-15 | Schering Corp | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY AND CENTRAL NERVOUS SYSTEM DISORDERS |
CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
JP2005526709A (en) | 2002-01-10 | 2005-09-08 | ニューロジェン・コーポレーション | Melanin-concentrating hormone receptor ligand: substituted benzimidazole analogs |
JP2005532991A (en) | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | Melanin-concentrating hormone receptor ligand: substituted 2- (4-benzyl-piperazin-1-ylmethyl)-and 2- (4-benzyl-diazepan-1-ylmethyl) -1H-benzimidazole analogs |
WO2003091216A1 (en) * | 2002-04-25 | 2003-11-06 | Sumitomo Pharmaceuticals Co., Ltd. | Novel piperidine derivative |
AU2003236247A1 (en) * | 2002-05-03 | 2003-11-17 | Warner-Lambert Company Llc | Bombesin antagonists |
GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US20060128752A1 (en) * | 2002-07-03 | 2006-06-15 | Giuseppe Alvaro | Chemical compounds |
WO2004028530A1 (en) | 2002-09-26 | 2004-04-08 | Bristol-Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
WO2004035566A1 (en) * | 2002-10-18 | 2004-04-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
PL376659A1 (en) * | 2002-11-06 | 2006-01-09 | Tularik Inc. | Fused heterocyclic compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JPWO2004069798A1 (en) * | 2003-02-10 | 2006-05-25 | 萬有製薬株式会社 | Melanin-concentrating hormone receptor antagonist containing piperidine derivative as active ingredient |
CA2517088A1 (en) * | 2003-02-28 | 2004-09-16 | Schering Corporation | Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
GB0310724D0 (en) * | 2003-05-09 | 2003-06-11 | Glaxo Group Ltd | Chemical compounds |
EP1648878B9 (en) * | 2003-07-24 | 2011-03-16 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
AR045496A1 (en) * | 2003-08-29 | 2005-11-02 | Schering Corp | ANALOLGES OF BENZIMIDAZOLPIPERIDINAS 2- SUBSTIZED AS ANTAGONISTS OF HORMONE RECEPTORS CONCENTRATING SELECTIVE MELANINE FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
ATE547404T1 (en) | 2003-09-22 | 2012-03-15 | Msd Kk | PIPERIDINE DERIVATIVES |
EP1729772B8 (en) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine glycine transporter inhibitors |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US20080096922A1 (en) * | 2004-04-06 | 2008-04-24 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Sulfonamide derivative |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008506702A (en) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | Method for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN101022802A (en) | 2004-07-22 | 2007-08-22 | Ptc医疗公司 | Thienopyridines for treating hepatitis c |
US7655644B2 (en) * | 2004-12-21 | 2010-02-02 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
NZ562766A (en) | 2005-05-30 | 2011-03-31 | Banyu Pharma Co Ltd | Piperidine derivatives as histamine-H3 receptor antagonists |
CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
EP1923388A4 (en) | 2005-08-12 | 2011-03-09 | Takeda Pharmaceutical | Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
BRPI0616463A2 (en) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | compound, pharmaceutical composition, and use of a compound |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
EP1942893A4 (en) * | 2005-10-28 | 2011-10-12 | Merck Sharp & Dohme | Piperidine glycine transporter inhibitors |
BRPI0618354B8 (en) | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | compound and its use, pharmaceutical composition, preventive or medicine |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
WO2007087066A2 (en) * | 2005-12-28 | 2007-08-02 | Vertex Pharmaceuticals Incorporated | 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (en) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | Diaryl ketimine derivatives |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
EP2152271B1 (en) * | 2007-06-08 | 2015-10-21 | Janssen Pharmaceutica, N.V. | Piperidine/piperazine derivatives |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
MX2011004258A (en) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Novel cyclic benzimidazole derivatives useful anti-diabetic agents. |
KR101320245B1 (en) | 2008-10-30 | 2013-10-30 | 머크 샤프 앤드 돔 코포레이션 | Isonicotinamide orexin receptor antagonists |
JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR20150075120A (en) | 2011-02-25 | 2015-07-02 | 머크 샤프 앤드 돔 코포레이션 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012158844A1 (en) | 2011-05-17 | 2012-11-22 | Shionogi & Co., Ltd. | Heterocyclic compounds |
AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
RU2015106909A (en) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC TRICYCLIC COMPOUNDS |
KR20150118158A (en) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
CA3189908A1 (en) | 2020-08-18 | 2022-02-24 | Stephane L. Bogen | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278541A (en) * | 1966-10-11 | Di-substituted-n-alkyl piperidines | ||
GB230714A (en) | 1924-08-20 | 1925-03-19 | Frederick Charles Bina | Improvements in propeller pencils |
GB640168A (en) * | 1946-07-30 | 1950-07-12 | Sterling Drug Inc | Improvements in or relating to the preparation of 4-aryl-4-aminomethyl-piperidine derivatives |
US2538107A (en) * | 1946-07-30 | 1951-01-16 | Sterling Drug Inc | 4 aryl-4-aminomethylpiperidine derivatives and their preparation |
US2634275A (en) * | 1951-11-07 | 1953-04-07 | Winthrop Stearns Inc | 4-acylamino-1-alkyl-4-phenylpi-peridines and method of making same |
NL262366A (en) * | 1960-03-14 | |||
FR1381445A (en) * | 1963-10-23 | 1964-12-14 | Hoechst Ag | Piperidine compounds and their preparation |
FR1477152A (en) * | 1965-04-23 | 1967-04-14 | Yoshitomi Pharmaceutical | Process for the preparation of indole derivatives |
US3455940A (en) * | 1965-12-07 | 1969-07-15 | Herbert C Stecker | Certain halo and dihalo n-substituted salicylamides |
US4069223A (en) * | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
FI97540C (en) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Process for the preparation of therapeutically useful aromatically substituted piperidine and piperazine derivatives |
SE8904298D0 (en) * | 1989-12-21 | 1989-12-21 | Astra Ab | NEW COMPOUNDS |
IL99320A (en) | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
FR2676054B1 (en) | 1991-05-03 | 1993-09-03 | Sanofi Elf | NOVEL N-ALKYLENEPIPERIDINO COMPOUNDS AND THEIR ENANTIOMERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2688219B1 (en) | 1992-03-03 | 1994-07-08 | Sanofi Elf | AMATONIUM QUATERNARY SALTS OF AMINO AROMATIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2719311B1 (en) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools. |
FR2717802B1 (en) | 1994-03-25 | 1996-06-21 | Sanofi Sa | New aromatic compounds, process for their preparation and pharmaceutical compositions containing them. |
SE9404438D0 (en) * | 1994-12-21 | 1994-12-21 | Astra Ab | New process |
FR2729954B1 (en) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO1996038471A1 (en) * | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
FR2738245B1 (en) | 1995-08-28 | 1997-11-21 | Sanofi Sa | NOVEL PIPERIDINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
AU5135998A (en) * | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
WO1999065494A1 (en) * | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
ID29137A (en) | 1998-07-27 | 2001-08-02 | Schering Corp | HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS |
US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
US6303637B1 (en) * | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
ATE314371T1 (en) | 1998-11-10 | 2006-01-15 | Merck & Co Inc | SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS |
-
2002
- 2002-04-10 EP EP02731318A patent/EP1377293B1/en not_active Expired - Lifetime
- 2002-04-10 CA CA2443672A patent/CA2443672C/en not_active Expired - Fee Related
- 2002-04-10 WO PCT/US2002/011296 patent/WO2002083134A1/en active Application Filing
- 2002-04-10 ES ES02731318T patent/ES2340147T3/en not_active Expired - Lifetime
- 2002-04-10 DE DE60235617T patent/DE60235617D1/en not_active Expired - Lifetime
- 2002-04-10 US US10/120,080 patent/US6887889B2/en not_active Expired - Fee Related
- 2002-04-10 AT AT02731318T patent/ATE460163T1/en not_active IP Right Cessation
- 2002-04-10 AR ARP020101318A patent/AR035234A1/en unknown
- 2002-04-10 PE PE2002000298A patent/PE20021081A1/en not_active Application Discontinuation
- 2002-04-10 MX MXPA03009353A patent/MXPA03009353A/en active IP Right Grant
- 2002-04-10 JP JP2002580938A patent/JP4280073B2/en not_active Expired - Fee Related
-
2009
- 2009-02-06 JP JP2009026802A patent/JP2009102430A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1377293B1 (en) | 2010-03-10 |
JP2009102430A (en) | 2009-05-14 |
DE60235617D1 (en) | 2010-04-22 |
ES2340147T3 (en) | 2010-05-31 |
CA2443672C (en) | 2011-03-29 |
AR035234A1 (en) | 2004-05-05 |
MXPA03009353A (en) | 2004-02-12 |
ATE460163T1 (en) | 2010-03-15 |
US20030013720A1 (en) | 2003-01-16 |
WO2002083134A1 (en) | 2002-10-24 |
CA2443672A1 (en) | 2002-10-24 |
US6887889B2 (en) | 2005-05-03 |
JP2004526761A (en) | 2004-09-02 |
EP1377293A1 (en) | 2004-01-07 |
JP4280073B2 (en) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20021081A1 (en) | ARIL AND BIARIL PIPERIDINES WITH MCH MODULATING ACTIVITY | |
NZ528851A (en) | N-aroyl cyclic amines | |
PE20040898A1 (en) | NEW COMPOUNDS DERIVED FROM PYRIMIDINE | |
PE20060438A1 (en) | UREA COMPOUNDS AS MODULATORS OF SARCOMER | |
PE20010741A1 (en) | PIPERAZINE DERIVATIVES AS ANTAGONISTS OF TACHYCININS | |
PE20030238A1 (en) | USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BRAIN, SPINAL AND NEURONAL INJURIES | |
PE20020589A1 (en) | 5-SPIROPYRIMIDIN-2,4,6-TRIONA AS INHIBITORS OF METALOPROTEINASES | |
CY1111075T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PRODUCTS OF 3-AMINO-AZETIDINE, THEIR NEW PRODUCTS, AND THEIR PREPARATION | |
PE20030809A1 (en) | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE (MCH) | |
NO20051223L (en) | Oxadiazoles as modulators of metabotropic glutamate receptor-5. | |
PE20060693A1 (en) | NEW DERIVATIVES OF TRIFLUOROMETANSULFONANILIDE OXAMIDE ETER | |
PE20021011A1 (en) | QUINAZOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | |
PE20071080A1 (en) | BICYCLE PYRIMIDINONE COMPOUNDS AS INHIBITORS OF HIV INTEGRASE | |
PE20050525A1 (en) | SUBSTITUTED PIRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS ANTAGONISTS OF THE BRADIQUININ B1 RECEPTOR | |
PE20060977A1 (en) | PIPERIDINYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | |
PE20030062A1 (en) | ARALKYLSULFONIL-3- (PYRROL-2-ILMETILIDEN) -2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | |
RU2008141151A (en) | N-HYDROXYLESULPHONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXIL DONORS | |
PE20090437A1 (en) | NON-BASIC MELANIN-CONCENTRATING HORMONE 1 RECEPTOR ANTAGONISTS AND PROCEDURES | |
PE58399A1 (en) | ATROPISOMERS OF 3-ARYL-4 (3H) -QUINAZOLINONES | |
PE20030012A1 (en) | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLOXOACETICO PIPERAZINE DERIVATIVES | |
PE20070341A1 (en) | PIRROL DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | |
PE20040988A1 (en) | NEW PYRAZOLE COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
DE60012751D1 (en) | USE OF EP4 RECEPTOR LIGANDS FOR TREATING NEUROPATHIC PAIN | |
PE20060770A1 (en) | DERIVATIVES OF N - [(4,5-DIPHENYL-3-ALKYL-2-THENYL) METHYL] AMINE AS ANTAGONISTS OF CB1 CANNABINOID RECEPTORS | |
IL197642A (en) | Heterocyclic derivatives and uses thereof in the preparation of pharmaceutical compositions for treating opioid receptor related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |